B. Riley Securities initiates coverage on Ascentage Pharma with Buy rating
B. Riley Securities analyst Mayank Mamtani has initiated coverage on Ascentage Pharma Group with a Buy rating and a price target of $45.
*this image is generated using AI for illustrative purposes only.
B. Riley Securities analyst Mayank Mamtani has initiated coverage on Ascentage Pharma Group with a Buy rating and a price target of $45. The rating highlights the firm's positive outlook on the company's stock performance.
Coverage Details
The initiation of coverage provides a new investment perspective on Ascentage Pharma Group. The price target of $45 serves as a benchmark for the stock's potential valuation.
| Analyst | Firm | Rating | Price Target |
|---|---|---|---|
| Mayank Mamtani | B. Riley Securities | Buy | $45 |
What key factors could drive Ascentage Pharma's stock to reach the $45 price target?
How might this new coverage impact investor sentiment and trading volume in the short term?
What upcoming clinical trial results or regulatory milestones could influence the stock's performance?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
